Ignite Creation Date:
2024-05-06 @ 3:53 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04797910
Status:
UNKNOWN
Last Update Posted:
2021-03-15
First Post:
2021-03-07
Brief Title:
Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis
Sponsor:
Nanfang Hospital Southern Medical University
Organization:
Nanfang Hospital Southern Medical University
Study Overview
Official Title:
Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis
Status:
UNKNOWN
Status Verified Date:
2021-03
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Complications associated with portal hypertension are the leading cause of death in patients with cirrhosis Until now hepatic venous pressure gradient HVPG - the difference between the wedged hepatic venous pressure WHVP and the free hepatic vein pressure FHVP- has been the criterion standard to determine portal pressure Antiviral therapy may decrease HVPG which needs to be verified
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None